Press
EpiVax Awarded Grant For Vaccine Engineering
Posted on September 17, 2017 by Annie De Groot$5.8 MILLION AWARDED FOR VACCINE ENGINEERING WILL USE “IMMUNE HISTORY” TO PROTECT AGAINST BIRD FLU, A COLLABORATION LED BY EPIVAX PROVIDENCE, R.I., Sept. 18, 2017– EpiVax, Inc. (“EpiVax”) a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine. H7N9 is distantly related to seasonal influenza ...Read moreEpiVax and EpiVax Oncology: Ready to Take on Cancer
Posted on August 22, 2017 by Admin EpivaxEpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology. EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. ...Read moreEpiVax: Best Place to Work 2017!
Posted on August 3, 2017 by Annie De GrootEpiVax: Best Place to Work 2017!Read moreEpiVax Awarded New “Innovation Voucher”
Posted on August 3, 2017 by Admin EpivaxAccelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of personalized cancer vaccines using in silico methods. In partnership with Rhode Island Hospital, EpiVax’s innovative project aims to identify cancer-specific targets, or neoantigens, capable of directing ...Read moreOptimized H7N9 induces higher Ab in humanized, but not standard, mice
Posted on May 24, 2017 by Annie De GrootA new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than vaccines developed for other subtypes of influenza. In previous work, we identified a key T-cell epitope in H7 hemagglutinin (HA) that ...Read moreHappy Birthday EpiVax! We’re Celebrating With a New Look!
Posted on May 18, 2017 by Admin EpivaxNineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were recently recognized as one of the 2017 Best Places to Work in Rhode Island, we are ...Read moreTregitope Takes a Step Toward the Clinic
Posted on April 25, 2017 by Annie De GrootEpiVax Signs First Commercial License for Tregitope Technology PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global pharmaceutical company, for use in autoimmune disease and allergy. Tregitopes, pronounced T·rej·itopes, are a set of peptides first discovered in human immunoglobulin by EpiVax CEO Annie De Groot and EpiVax CIO Bill Martin. ...Read moreEpiVax Signs First Commercial License for Tregitope Technology
Posted on April 7, 2017 by Annie De GrootProvidence, RI April 7th, 2017 Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an unnamed global pharmaceutical company, for use in autoimmune disease and allergy. Tregitopes, pronounced T·rej·itopes, are a set of peptides first discovered in human immunoglobulin by EpiVax CEO Annie De Groot and EpiVax CIO Bill Martin. Similar to intravenous immunoglobulin G, ...Read moreBARDA, WHO, CDC and H7N9: Doing the Same Thing All Over Again?
Posted on March 7, 2017 by Annie De Groot“Insanity: doing the same thing over and over again and expecting different results.” – Albert Einstein. Due to its high rate of lethality (30-40%) and pandemic potential, H7N9 preparedness has become a priority for public health officials. While mutations that would enable human to human transmission by the avian strain have not yet occurred, CDC placed H7N9 at the ...Read more5th Annual NTD/EID Workshop
Posted on February 20, 2017 by Annie De Groot5th Annual NTD/EID Computational Vaccinology Workshop May 15th – 19th, 2017 iCubed, 80 Washington Street Providence RI, United States The Institute for Immunology and Informatics (iCubed) will once again be hosting our training workshop in vaccine design for Neglected Tropical Diseases and Emerging Infectious Diseases (NTD/EID) This May, the Institute for Immunology and Informatics (iCubed) will once again be hosting a training workshop in ...Read moreEpiVax at Bio Asia 2017
Posted on February 20, 2017 by Annie De GrootLucky us! the 14th International Bio Asia Conference is scheduled for March 14-15, 2017 at the Grand Hyatt, Tokyo in Roppongi. It might be a bit early for cherry blossoms, but hope springs eternal! We will be arriving a bit early and staying a bit late. Please let us know if you would like us to meet with you ...Read moreOur Prediction for 2017: Out with Post Hoc and Go DeFT!
Posted on February 10, 2017 by Admin EpivaxIt’s a new year and welcome to it! Pundits are making a lot of predictions about the decline of science and technology under the new administration in Washington DC, and I’m here with a contrarian view. We bet on biotechnology! We predict that the next four years will see a revolution and acceleration of innovation, regardless of ...Read moreWill EpiVax Tools be the Ancer to Cancer?
Posted on January 2, 2017 by Annie De GrootEpiVax Oncology – New Year, New Endeavor! A nice story in ConvergenceRI that describes the rapid growth of EpiVax and our decision to invest in a new spin-out company in 2017: Welcome EpiVax Oncology! Annie was interviewed by Richard Asinof about “EpiVax Oncology” in the Epibar: link to the full story here, and read more about the ...Read more$1.87M BioDefense Grant to EpiVax and CUBRC
Posted on December 19, 2016 by Annie De GrootCUBRC and EpiVax Awarded DTRA Grant worth $1.87 Million to Perform Research into Vaccine Antigen Design for Burkholderia pseudomallei Buffalo, NY – December 19, 2017 – CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC’s Biological and Medical Sciences team, in collaboration with EpiVax, Inc., has received a four-year grant worth $1.87 million from ...Read moreThe Ancer to Cancer: A computational pipeline for personalized cancer vaccine design
Posted on December 11, 2016 by Annie De GrootBuilding on 18 years of commercially successful research and development in the field of computational immunology, EpiVax has now developed Ancer™, a personalized cancer vaccine platform. Ancer is a high-speed, secure, cloud-based commercial platform for processing cancer/normal protein sets, identifying high-quality patient-specific neo-antigens, and designing personalized cancer vaccines. EpiVax has established a reputation for innovative cloud-based ...Read more
Join our newsletter
We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.